Condensed Consolidated Statements of Income and Reconciliation of GAAP Earnings to "Adjusted" Earnings (In millions, except per share data) (Unaudited)

				Months ember 30					Three Months Ended September 30, 2009								
_	(GAAP		Adjustmer	nts	"Ac	djusted"			GAAP	Adjustments			"Adjusted"			
Revenues:	•	0.750	•			Φ.	0.750		æ	0.700	Φ.			œ.	0.700		
Product sales Other revenues	\$	3,759 57	\$	-		\$	3,759 57		\$	3,736 76	\$	-		\$	3,736 76		
Total revenues		3,816					3,816			3,812		- -			3,812		
		0,0.0					0,0.0			0,0.2					0,0.2		
Operating expenses:																	
Cost of sales (excludes amortization of certain																	
acquired intangible assets presented below)		587		(3)	(a)		584			545		(3)	(a)		542		
Research and development		719		(12)	(a)		689			647		(13)	(a)		613		
				(18)	(b)							(18)	(b)				
												(3)	(f)				
Selling, general and administrative		957		(15)	(a)		942			932		(13)	(a)		913		
												(6)	(f)				
Amortization of certain acquired intangible assets		74		(74)	(c)		-			74		(74)	(c)		-		
Other		-		-			-			9		(8)	(e)		-		
												(1)	(f)				
Total operating expenses		2,337		(122)			2,215			2,207		(139)			2,068		
Operating income		1,479		122			1,601			1,605		139			1,744		
Interest expense, net		150		(67)	(d)		83			139		(63)	(d)		76		
Interest and other income, net		105		-	(u)		105			74		-	(α)		74		
Income before income taxes		1,434		189			1,623			1,540		202			1,742		
Provision for income taxes		198		74	(g)		310			154		80	(h)		224		
				38	(i)							(28) 18	(i) (k)				
												10	(.,)				
Net income	\$	1,236	\$	77		\$	1,313		\$	1,386	\$	132		\$	1,518	•	
Earnings per share:																	
Basic	\$	1.29				\$	1.37		\$	1.36				\$	1.49		
Diluted (I)	\$	1.28				\$	1.36	(a)	\$	1.36				\$	1.49	(a)	
Average shares used in calculation																	
of earnings per share:																	
Basic		958					958			1,016					1,016		
Diluted (I)		962					962	(a)		1,022					1,021	(a)	

⁽a) - (l) See explanatory notes on the following pages.



Amgen Inc. Condensed Consolidated Statements of Income and Reconciliation of GAAP Earnings to "Adjusted" Earnings (In millions, except per share data) (Unaudited)

	Nine months ended September 30, 2010									Nine months ended September 30, 2009									
_		GAAP		Adjustmer	nts	"Ac	djusted"			GAAP	Adjustments			"Adjusted"					
Revenues: Product sales	\$	10,900	\$	_		\$	10,900		\$	10,608	\$	_		\$	10,608				
Other revenues	Ψ	312	Ψ	-		Ψ	312		Ψ	225	Ψ	-		Ψ	225				
Total revenues		11,212					11,212			10,833		-			10,833				
Cost of sales (excludes amortization of certain																			
acquired intangible assets presented below)		1,648		(11)	(a)		1,637			1,553		(9) (1)	(a) (f)		1,543				
Research and development		2,040		(40) (52)	(a) (b)		1,948			1,973		(40) (52) (6)	(a) (b) (f)		1,875				
Selling, general and administrative		2,827		(44)	(a)		2,783			2,640		(39)	(a) (f)		2,578				
Amortization of certain acquired intangible assets Other		221 (1)		(221) 1	(c) (e)		-			221 63		(221) (28) (35)	(c) (e) (f)		-				
Total operating expenses		6,735		(367)			6,368			6,450		(454)	()		5,996				
Operating income		4,477		367			4,844			4,383		454			4,837				
Interest expense, net		442 283		(198)	(d)		244 283			436 182		(186)	(d)		250 182				
Income before income taxes		4,318		565			4,883			4,129		640			4,769				
Provision for income taxes		713		211 38	(g) (i)		962			455		235 87 25 18	(h) (i) (j) (k)		820	•			
Net income	\$	3,605	\$	316		\$	3,921		\$	3,674	\$	275		\$	3,949				
Earnings per share:																			
Basic Diluted (I)	\$ \$	3.73 3.71				\$ \$	4.06 4.04	(a)	\$ \$	3.60 3.58				\$ \$	3.87 3.86	(a)			
Average shares used in calculation of earnings per share:																			
Basic		966 971					966 971	(a)		1,020 1,025					1,020 1,024	(a)			

⁽a) - (l) See explanatory notes on the following pages.



Amgen Inc.
Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
(In millions, except per share data)
(Unaudited)

(a) To exclude stock option expense. For the three and nine months ended September 30, 2010 and 2009, the total pre-tax expense for employee stock options was \$30 million and \$95 million, respectively, and \$29 million and \$88 million, respectively.

"Adjusted" diluted EPS including the impact of stock option expense for the three and nine months ended September 30, 2010 and 2009 was as follows:

	Three mon Septem			Nine mon Septem		
	2010	:	2009	2010	- 2	2009
"Adjusted" diluted EPS, excluding stock option expense	\$ 1.36	\$	1.49	\$ 4.04	\$	3.86
Impact of stock option expense (net of tax)	 (0.01)		(0.02)	 (0.07)		(0.06)
"Adjusted" diluted EPS, including stock option expense	\$ 1.35	\$	1.47	\$ 3.97	\$	3.80

- (b) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets with alternative future uses acquired with the acquisitions of Abgenix, Inc. ("Abgenix") and Avidia, Inc. ("Avidia").
- (c) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex Corporation ("Immunex") acquisition.
- (d) To exclude the incremental non-cash interest expense resulting from a change in the accounting for our convertible notes effective January 1, 2009.
- (e) To exclude loss accruals or awards for legal settlements.
- (f) To exclude the expenses associated with our restructuring plan announced in August 2007 and certain additional cost savings initiatives subsequently identified.
- (g) To reflect the tax effect of the above adjustments for 2010.
- (h) To reflect the tax effect of the above adjustments for 2009.
- (i) To exclude the income tax benefit (expense) recognized as a result of resolving certain non-routine transfer pricing issues with tax authorities for prior periods.
- (j) To exclude the net tax benefit resulting from adjustments to previously established deferred taxes, primarily related to prior acquisitions and stock option expense, due to changes in California tax law effective for future periods.
- (k) To exclude the tax benefit principally related to certain prior period charges excluded from "Adjusted" earnings.
- (I) The following table presents the computations for GAAP and "Adjusted" diluted earnings per share, computed under the treasury stock method. "Adjusted" earnings per share presented below excludes stock option expense:

	Three mor				Three mor		
	 GAAP	"Ac	ljusted"	GAAP		"Ad	ljusted"
Income (Numerator):							
Net income for basic and diluted EPS	\$ 1,236	\$	1,313	\$	1,386	\$	1,518
Shares (Denominator):							
Weighted-average shares for basic EPS	958		958		1,016		1,016
Effect of dilutive securities	4		4 (+	:)	6		5 (*)
Weighted-average shares for diluted EPS	962		962		1,022		1,021
Diluted earnings per share	\$ 1.28	\$	1.36	\$	1.36	\$	1.49

		Nine mont Septembe				ded 009		
	G	AAP	"Adjusted"		G	AAP	"Ad	justed"
Income (Numerator):								
Net income for basic and diluted EPS	\$	3,605	\$	3,921	\$	3,674	\$	3,949
Shares (Denominator):								
Weighted-average shares for basic EPS		966		966		1,020		1,020
Effect of dilutive securities		5		5 (*)	5		4 (*)
Weighted-average shares for diluted EPS	_	971	_	971	_	1,025		1,024
Diluted earnings per share	\$	3.71	\$	4.04	\$	3.58	\$	3.86

(*) Dilutive securities used to compute "Adjusted" diluted earnings per share for the three and nine months ended September 30, 2010 and 2009 were computed under the treasury stock method assuming that we do not expense stock options.



	Three m				end r 30,	nded 30,		
	2010		2009	2010				2009
Aranesp® - U.S.	\$ 283		\$ 333	\$	818		\$	963
Aranesp® - International	340		352		1,035			1,041
EPOGEN® - U.S	653		663		1,933			1,866
Neulasta® - U.S	692		657		1,972			1,876
NEUPOGEN® - U.S.	250		240		700			672
Neulasta® - International	224		214		668			603
NEUPOGEN® - International	88		99		267			290
Enbrel® - U.S	856		872		2,429			2,430
Enbrel® - Canada	58		52		166			151
Sensipar® - U.S	115		108		344			320
Sensipar® - International	60		57		182			160
Vectibix® - U.S.	30		23		84			72
Vectibix® - International	40		35		125			95
Nplate® - U.S	35		22		95			54
Nplate® - International	25		9		69			15
Prolia™ - U.S.	7		-		10			-
Prolia [®] - International	 3		 		3			
Total product sales	\$ 3,759		\$ 3,736	\$	10,900		\$	10,608
U.S.	\$ 2,921		\$ 2,918	\$	8,385		\$	8,253
International	838	(a)	818		2,515	(b)		2,355
Total product sales	\$ 3,759			\$			\$	10,608

⁽a) The change in international product sales for the three months ended September 30, 2010 was negatively impacted by \$16 million due to unfavorable impact of foreign exchange (including \$7 million for Aranesp®, \$6 million for Neulasta®/NEUPOGEN®, \$3 million for Sensipar®, \$1 million for Vectibix® and \$1 million for Nplate®, partially offset by favorable impact of \$2 million for ENBREL).



⁽b) The change in international product sales for the nine months ended September 30, 2010 was positively impacted by \$34 million due to favorable impact of in foreign exchange (including \$15 million for Neulasta®/ NEUPOGEN®, \$12 million for Aranesp® and \$8 million for ENBREL, partially offset by unfavorable impact of \$1 million for Sensipar®).

Condensed Consolidated Balance Sheets - GAAP (In millions) (Unaudited)

	Sept	ember 30, 2010	Dec	ember 31, 2009
Assets		_		
Current assets:				
Cash, cash equivalents and marketable securities	\$	17,049	\$	13,442
Trade receivables, net		2,443		2,109
Inventories		2,044		2,220
Other current assets		1,394		1,161
Total current assets		22,930		18,932
Property, plant and equipment, net		5,643		5,738
Intangible assets, net		2,315		2,567
Goodwill		11,334		11,335
Other assets		1,312		1,057
Total assets	\$	43,534	\$	39,629
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable and accrued liabilities	\$	3,809	\$	3,873
Current portion of convertible notes	Ψ	2,451	Ψ	-
Total current liabilities		6,260	-	3,873
Convertible notes		2,263		4,512
Other long-term debt		8,578		6,089
Other non-current liabilities.		2,362		2,488
Stockholders' equity		24,071		22,667
Total liabilities and stockholders' equity	\$	43,534	\$	39,629
Shares outstanding		952		995



(Unaudited)

			Septen	nber 30, 20	10			September 30, 2009								
			ments for				Adjustments for									
			acc	ounting				accounting								
	(GAAP	sta	standard		"Adjusted"		GAAP		standard		P	Adjusted"			
Total debt outstanding	\$	13,292	\$	368	(a)	\$	13,660	\$	11,536	\$	635 (a)	\$	12,171			

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.

Amgen Inc.

Reconciliation of GAAP Stockholders' equity to Stockholders' equity as adjusted for impact of accounting standard (In millions)
(Unaudited)

	September 30, 2010							September 30, 2009										
	Adjustments for						Adjustments for											
			accounting					accounting										
		GAAP	sta	standard		"Adjusted"		GAAP		sta	indard	"Ac	djusted"					
Stockholders' equity	\$	24,071	\$	(220)	(a)	\$	23,851	\$	22,858	\$	(383) (a)	\$	22,475					

(a) To exclude the impact of adopting an accounting standard on January 1, 2009 that changed the method of accounting for our convertible notes.



Reconciliation of GAAP Earnings Per Share Guidance to "Adjusted" Earnings Per Share Guidance for the Year Ending December 31, 2010 (Unaudited)

On October 25, 2010, the Company reaffirmed its "Adjusted" earnings per share guidance towards lower end of \$5.05 to \$5.25, including the estimated impact of the U.S. Health Care Reform Legislation of slightly below \$200 million. The following table shows a reconciliation of GAAP earnings per share (diluted) guidance to "Adjusted" earnings per share (diluted) guidance.

		 20		
GAAP earnings per share (diluted) guidance		\$ 4.59	-	\$ 4.80
Known adjustments to arrive at "Adjusted" earnings*:				
Amortization of acquired intangible assets, product technology rights	(a)			0.19
Incremental non-cash interest expense	(b)			0.17
Stock option expense	(c)	0.08	-	0.09
Amortization of acquired intangible assets, R&D technology rights	(d)			0.05
Tax settlement	(e)			(0.04)
"Adjusted" earnings per share (diluted) guidance		\$ 5.05		\$ 5.25

- * The known adjustments are presented, where applicable, net of their related aggregate tax impact of approximately \$0.28 to \$0.29 per share.
- (a) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex acquisition.
- (b) To exclude the incremental non-cash interest expense resulting from a change in accounting in January 2009 related to our convertible debt.
- (c) To exclude stock option expense.
- (d) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with the Abgenix and Avidia acquisitions.
- (e) To exclude the income tax benefit recognized as a result of resolving certain non-routine transfer pricing issues with tax authorities for prior periods.

Amgen Inc.

Reconciliation of GAAP Tax Rate Guidance to "Adjusted" Tax Rate Guidance for the Year Ending December 31, 2010 (Unaudited)

On October 25, 2010, the Company stated that it now expects its "Adjusted" tax rate guidance to be around 20%. The tax rate effect of known adjustments discussed above is approximately 3%, resulting in GAAP tax rate guidance of approximately 17%.

